Effect of follicle-stimulating hormone dose on the risk of being classified as suboptimal responders according to the POSEIDON criteria


Hochberg A., Dahan M. H., Yarali H., Vuong L. N., Esteves S. C.

JOURNAL OF ASSISTED REPRODUCTION AND GENETICS, vol.41, pp.3387-3398, 2024 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 41
  • Publication Date: 2024
  • Doi Number: 10.1007/s10815-024-03296-2
  • Journal Name: JOURNAL OF ASSISTED REPRODUCTION AND GENETICS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, ATLA Religion Database, BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.3387-3398
  • Hacettepe University Affiliated: Yes

Abstract

Purpose The purpose of this study is to investigate the impact of daily follicle-stimulating-hormone (FSH) dose on the likelihood of suboptimal response to ovarian stimulation (OS) for in vitro fertilization (IVF) according to POSEIDON's criteria. Methods A tri-center retrospective cohort study (2015-2017) including women with normal anti-M & uuml;llerian hormone (AMH >= 1.2 ng/mL) and antral follicle count (AFC >= 5) values per POSEIDON's criteria, undergoing their first IVF/ICSI cycle using conventional OS (FSH >= 150 IU/day). Suboptimal response was the retrieval of 4-9 oocytes. In previous research, we detected an AMH <= 2.97 ng/mL and AFC <= 12 as the optimal cut-offs predicting suboptimal response. Therefore, we examined the effect of daily FSH dose (<= 300 IU versus > 300 IU) on suboptimal response risk for each AMH and AFC value within these thresholds (AMH between 1.20 and 2.97 ng/mL, by 0.01 ng/mL increments; and an AFC between 5 and 12, by unit increments). Analysis involved contingency tables and multivariable logistic regression. Results Included were 4005 patients with AMH and AFC values in the specific range, among whom 2131 (53.2%) were suboptimal responders. Among 177 AMH groups analyzed, apart from three distributed irregularly, daily FSH doses > 300 IU versus lower doses (<= 300 IU) did not decrease suboptimal response risk; similarly, higher doses did not decrease risk at the eight AFC values examined (p > 0.05 for all). Using multivariable logistic regression, FSH doses were not associated with suboptimal response risk. Conversely, female age, AMH, AFC, and gonadotropin type were associated with suboptimal response. Conclusions In women with AMH values between 1.20 and 2.97 ng/mL and/or AFC between 5 and 12, FSH dose increase did not decrease suboptimal response risk. Individualizing the gonadotropin regimen and considering LH activity supplementation to FSH may mitigate risks.